## Contents

### Commentaries
- **s1** Heated tobacco products: the example of IQOS
  S A Glantz
- **s7** Heated tobacco products: things we do and do not know
  I Stepanov, A Woodwards

### Research papers
- **s9** PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes
  S A Glantz
- **s13** Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke
  P Nahovitzadeh, J Liu, C M Havel, S Ibrahim, R Derakhshandeh, P Jacob III, M L Springer
- **s20** Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
  F Aloaez, L Chun, M A Manthey, C S Califfee, J Gots
- **s30** IQOS: examination of Philip Morris International’s claim of reduced exposure
  G St.Helen, P Jacob III, N Nardone, N L Benowitz
- **s41** Heated tobacco products likely appeal to adolescents and young adults
  K McKelvey, L Popova, M Kim, B W Chatfee, M Vijayaraghavan, P Ling, B Halpern-Felsher
- **s48** IQOS labelling will mislead consumers
  K McKelvey, L Popova, M Kim, L K Lampert, B W Chatfee, M Vijayaraghavan, P Ling, B Halpern-Felsher
- **s55** Awareness and use of heated tobacco products among US adults, 2016–2017
  A L Nymea, S R Weaver, L Popova, T F Pechacek, J Huang, D L Ashley, M P Eriksen
- **s62** Impact of modified risk tobacco product claims on beliefs of US adults and adolescents
  S EL-Toukhy, S A Baig, M Jeong, M J Byron, K M Rabold, N T Brewer
- **s70** Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland
  E C Hair, M Bennett, E Sheen, J Cornell, J Briggs, Z Fenn, J G Willet, D Vallone

### Brief reports
- **s26** Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells
  N J Leigh, P L Tran, R J O’Connor, M J Glantz
- **s74** Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults
  J Kim, H Yu, S Lee, Y-J Park

### Research letters
- **s37** Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS
  N J Leigh, M N Palmbe, A M Manno, R J O’Connor, M J Glantz
- **s39** Possible hepatotoxicity of IQOS
  L Chun, F Aloaez, M Manthey, C Califfee, J Gots

### Industry watch
- **s78** IQOS campaign in Israel
  L J Rosen, S Kaliev

### Special communication
- **s111** Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control
  S A Bialous, S A Glantz
- **s118** Heated tobacco product regulation under US law and the FTC
  L K Lampert, S A Glantz

---

**November 2018 Volume 27 Issue S1**

- **s82** Modelling the impact of a new tobacco product: review of Philip Morris International’s Population Health Impact Model as applied to the IQOS heated tobacco product
  W B Maze, H-Y Sung, J Lightwood, Y Wang, T Yee
- **s87** Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims
  I Popova, L K Lampert, S A Glantz
- **s96** Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products
  J Elias, P M Ling
- **s102** Revolution or redux? Assessing IQOS through a precursor product
  J Elias, I M Dutra, G St. Helen, P M Ling

---

**Cover credit:** Cover created by Jonathan Polansky, OnBeyond LLC.